The Latest Headlines at American Banking and Market News
Church & Dwight (NYSE:CHD) Given New $120.00 Price Target at Oppenheimer
Church & Dwight (NYSE:CHD – Free Report) had its target price increased by Oppenheimer from $110.00 to $120.00 in a report released on Tuesday morning, Benzinga reports. Oppenheimer currently has an outperform rating on... More of this article »
Bank of Hawaii (NYSE:BOH) Price Target Cut to $60.00 by Analysts at Piper Sandler
Bank of Hawaii (NYSE:BOH – Free Report) had its price objective trimmed by Piper Sandler from $65.00 to $60.00 in a report issued on Tuesday morning, Benzinga reports. The firm currently has a neutral rating on the bank’s... More of this article »
Insmed (NASDAQ:INSM) Receives New Coverage from Analysts at Truist Financial
Truist Financial began coverage on shares of Insmed (NASDAQ:INSM – Free Report) in a research report released on Tuesday, MarketBeat.com reports. The brokerage issued a buy rating and a $48.00 price objective on the biopharmaceutical... More of this article »
Incyte (NASDAQ:INCY) Now Covered by Analysts at Cantor Fitzgerald
Cantor Fitzgerald began coverage on shares of Incyte (NASDAQ:INCY – Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a neutral rating on the biopharmaceutical company’s... More of this article »
NICE (NASDAQ:NICE) Receives New Coverage from Analysts at Rosenblatt Securities
Rosenblatt Securities began coverage on shares of NICE (NASDAQ:NICE – Free Report) in a research note published on Tuesday, Marketbeat Ratings reports. The firm issued a buy rating and a $285.00 target price on the technology... More of this article »
Cartesian Therapeutics (NASDAQ:RNAC) Now Covered by Analysts at SVB Leerink
SVB Leerink assumed coverage on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report issued on Tuesday, Marketbeat reports. The firm issued an outperform rating and a $39.00 target price on the stock. Several... More of this article »
Harley-Davidson (NYSE:HOG) Coverage Initiated by Analysts at Morgan Stanley
Morgan Stanley started coverage on shares of Harley-Davidson (NYSE:HOG – Free Report) in a report published on Tuesday morning, Marketbeat.com reports. The firm issued an overweight rating and a $50.00 target price on the stock. Several... More of this article »
Rentokil Initial (NYSE:RTO) Coverage Initiated by Analysts at JPMorgan Chase & Co.
JPMorgan Chase & Co. began coverage on shares of Rentokil Initial (NYSE:RTO – Free Report) in a research note released on Tuesday morning, StockNewsAPI reports. The brokerage issued a neutral rating on the stock. A number... More of this article »
Heron Therapeutics (NASDAQ:HRTX) Coverage Initiated by Analysts at Capital One Financial
Capital One Financial began coverage on shares of Heron Therapeutics (NASDAQ:HRTX – Free Report) in a research note released on Tuesday, MarketBeat reports. The brokerage issued an overweight rating and a $6.00 price target on... More of this article »
First Advantage (NYSE:FA) Coverage Initiated by Analysts at William Blair
William Blair began coverage on shares of First Advantage (NYSE:FA – Free Report) in a research report released on Tuesday, MarketBeat reports. The brokerage issued an outperform rating on the stock. Several other research analysts... More of this article »
QUALCOMM (NASDAQ:QCOM) Receives New Coverage from Analysts at Benchmark
Benchmark started coverage on shares of QUALCOMM (NASDAQ:QCOM – Free Report) in a research note published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $200.00 target price on the wireless technology... More of this article »
Gain Therapeutics’ (GANX) “Outperform” Rating Reaffirmed at Oppenheimer
Oppenheimer reissued their outperform rating on shares of Gain Therapeutics (NASDAQ:GANX – Free Report) in a report published on Tuesday morning, Benzinga reports. The brokerage currently has a $9.00 price objective on the stock. Several... More of this article »
Fate Therapeutics (NASDAQ:FATE) Given “Neutral” Rating at Wedbush
Wedbush reiterated their neutral rating on shares of Fate Therapeutics (NASDAQ:FATE – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $7.00 price target on the biopharmaceutical... More of this article »